Aptalis’ Ultresa And Viokace Join Crowded Marketplace Of Pancreatic Enzyme Products
This article was originally published in The Pink Sheet Daily
The fourth and fifth products FDA has approved to treat pancreatic insufficiency join products made by Aptalis, Janssen Pharmaceuticals and Abbott GmbH.
You may also be interested in...
Ikaria shareholders sold the commercial side of that critical care business, but retained a stake in the off-loaded assets. While gastrointestinal and cystic fibrosis company Aptalis turns to an IPO instead of an acquisition.
A report suggests that Aptalis Pharma is on the block, but is the price too high? Also, Quintiles spends some of its IPO war chest on a smaller North Carolina CRO, and Pfizer strikes a diabetes deal with Sanford-Burnham.